RGDXQ (Response Genetics) Receivables Turnover: 0.00 (As of Dec. 2015)


What is Response Genetics Receivables Turnover?

Response Genetics RGDXQ -98.00% Receivables Turnover is 0.00 as of Dec. 2015.

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Response Genetics's Revenue for the three months ended in Dec. 2015 was $0.00 Mil. Response Genetics's average Accounts Receivable for the three months ended in Dec. 2015 was $6.34 Mil.

Response Genetics  (OTCPK:RGDXQ) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Response Genetics Receivables Turnover Related Terms

Response Genetics Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Response Genetics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics Receivables Turnover Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.16 3.98 1.14 1.81 3.10

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.67 0.00 0.68 0.00

RGDXQ vs PSID, GBSN, ETAH: Receivables Turnover Comparison

For the Diagnostics & Research subindustry, Response Genetics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Response Genetics Receivables Turnover vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Response Genetics's Receivables Turnover falls into.


Response Genetics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Response Genetics's Receivables Turnover for the fiscal year that ended in Dec. 2015 is calculated as

Receivables Turnover (A: Dec. 2015 )
=Revenue / Average Accounts Receivable
=Revenue (A: Dec. 2015 ) / ((Accounts Receivable (A: Dec. 2014 ) + Accounts Receivable (A: Dec. 2015 )) / count )
=18.04 / ((5.028 + 6.621) / 2 )
=18.04 / 5.8245
=3.10

Response Genetics's Receivables Turnover for the quarter that ended in Dec. 2015 is calculated as

Receivables Turnover (Q: Dec. 2015 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Dec. 2015 ) / ((Accounts Receivable (Q: Mar. 2015 ) + Accounts Receivable (Q: Dec. 2015 )) / count )
=0 / ((6.059 + 6.621) / 2 )
=0 / 6.34
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Receivables Turnover →
What does a Receivables Turnover of 0.00 mean?
Response Genetics (RGDXQ) has a Receivables Turnover of 0.00 as of Dec. 2015. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Response Genetics and its competitors.
Is Response Genetics' Receivables Turnover too high?
Response Genetics' current Receivables Turnover is 0.00.
How does Response Genetics' Receivables Turnover compare to PSID and GBSN?
Response Genetics' Receivables Turnover of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Receivables Turnover is 5.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.39, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Response Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Response Genetics's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Receivables Turnover is 0.00 as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.